20 November, 2018
NCT02096042 (Clinical Trials/ Brentuximab vedotin)
Phase I/II – Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML) (NCT02096042)
This clinical research study is made up of 3 phases: a Pilot Phase, Phase I, and Phase II trial.
The goal of the Pilot Phase is to learn how safe it is to give the study drug brentuximab vedotin (also known as SGN-035) to patients with Acute Myeloid Leukemia or AML. The goal of Phase I is to learn more about the safety of the combination of brentuximab vedotin with azacytidine. The goal of Phase II is to learn if the combination of brentuximab vedotin and azacytidine can help to control AML.
- Condition: Leukemia
- Phase: I & II
- Estimated Enrollment: 61
- Start: April 2014
- Estimated Primary Completion: April 2019 (Final data collection date for primary outcome measure
- Last verified: May 2015
Last Editorial review: July 11, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.
05 October, 2018
When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000, only a handful of patent applications claiming ADCs had been published. As research cont...